New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Aclaris Therapeutics, Inc.

Contributing Author

Recent Articles by Aclaris Therapeutics, Inc.

Sep-09	Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress ACRS GlobeNewswire
Aug-27	Aclaris Therapeutics to Participate in Two September Healthcare Conferences ACRS GlobeNewswire
Aug-07	Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire
Jul-29	Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints ACRS GlobeNewswire
Jul-28	Aclaris Therapeutics Announces Leadership Transition ACRS GlobeNewswire
Jun-30	Aclaris Therapeutics Added to the Russell 2000 and Russell 3000 Indexes ACRS GlobeNewswire
Jun-26	Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference ACRS GlobeNewswire
Jun-23	Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 ACRS GlobeNewswire
Jun-02	Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis ACRS GlobeNewswire
May-28	Aclaris Therapeutics to Participate in Two June Healthcare Conferences ACRS GlobeNewswire
May-09	Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series ACRS GlobeNewswire
May-08	Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.